Radium-223 Real World Studies Alpha Emitter Radium-223 and Survival in Metastatic Prost...Safety and Survival of 177Lu-PSMA Therapy in Metastatic C...Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castrati...Clinical outcomes and treatment patterns in REASSURE: pla...Radium-223 in combination with therapies for metastatic c...Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an internation...Radium-223 for asymptomatic castration-resistant prostate...Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an inter...Overall Survival Analysis by Number of Radium-223 Injecti...Analysis of overall survival by number of radium-223 injections received in an international expanded access program ...Real-world evaluation of access-driven Canadian treatment...Population-Based Study on Radium-223 Use in Metastatic Ca...A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associa...Population-Based Analysis of Radium-223 for Bone-Metastat...Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontari...Clinical Outcome Patterns of Use of Radium-223 in Patient...Single-Center Multidisciplinary Experience with Radium-22...A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant pr...Clinicopathologic factors that influence prognosis and su...Pain response in a population-based study of radium-223 (...
